J. Albrecht

622 total citations
18 papers, 449 citations indexed

About

J. Albrecht is a scholar working on Hepatology, Epidemiology and Immunology. According to data from OpenAlex, J. Albrecht has authored 18 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hepatology, 10 papers in Epidemiology and 4 papers in Immunology. Recurrent topics in J. Albrecht's work include Hepatitis C virus research (12 papers), Hepatitis B Virus Studies (7 papers) and Chronic Lymphocytic Leukemia Research (3 papers). J. Albrecht is often cited by papers focused on Hepatitis C virus research (12 papers), Hepatitis B Virus Studies (7 papers) and Chronic Lymphocytic Leukemia Research (3 papers). J. Albrecht collaborates with scholars based in United States, Germany and Spain. J. Albrecht's co-authors include E. Schiff, E. Läwitz, Jonathan McCone, Ira M. Jacobson, Raymond A. Rubin, Karen L. Lindsay, Joseph Galati, John M. Vierling, Robert P. McBurney and T. Jake Liang and has published in prestigious journals such as Blood, Hepatology and Journal of Hepatology.

In The Last Decade

J. Albrecht

17 papers receiving 437 citations

Peers

J. Albrecht

HEPAT

EPIDE

RHEUM

M. Willems Belgium

Stefan Zeuzem Germany

Eirum Chaudhri Japan

I. Ketikoglou Greece

D. Perner Germany

W. Petry Germany

Takeaki Satoh Japan

Zu-Yau Lin Taiwan

Rie Mineta Japan

Fernando Sogari Italy

M. Willems Belgium

J. Albrecht

257 ×0.7

HEPAT

215 ×0.6

EPIDE

36 ×0.6

37 ×0.7

RHEUM

42 ×1.3

Citations per year, relative to J. Albrecht J. Albrecht (= 1×) peers M. Willems

Countries citing papers authored by J. Albrecht

Since Specialization

Citations

This map shows the geographic impact of J. Albrecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Albrecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Albrecht more than expected).

Fields of papers citing papers by J. Albrecht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Albrecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Albrecht. The network helps show where J. Albrecht may publish in the future.

Co-authorship network of co-authors of J. Albrecht

This figure shows the co-authorship network connecting the top 25 collaborators of J. Albrecht. A scholar is included among the top collaborators of J. Albrecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Albrecht. J. Albrecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Nicolay, Jan P., Susanne Melchers, J. Albrecht, et al.. (2023). Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study. Blood. 142(9). 794–805. 24 indexed citations

Bazinet, Michel, Victor Pântea, Valentin Cebotarescu, et al.. (2016). Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV Co-Infection. Journal of Hepatology. 64(2). S584–S585. 9 indexed citations

Heller, Theo, Yaron Rotman, Christopher Koh, et al.. (2014). Long-term therapy of chronic delta hepatitis with peginterferon alfa. Alimentary Pharmacology & Therapeutics. 40(1). 93–104. 81 indexed citations

Brass, Clifford A., Richard J. O. Barnard, John A. Howe, et al.. (2011). 1194 SUSTAINED VIROLOGIC RESPONSE AND BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS OBSERVED IN PATIENTS INFECTED WITH HCV GENOTPYPE 1A/1B WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN. Journal of Hepatology. 54. S471–S472. 9 indexed citations

Howe, John A., Ping Qiu, Robert A. Ogert, et al.. (2011). 433 FREQUENCIES OF RESISTANCE-ASSOCIATED AMINO ACID VARIANTS DETECTED BY 454-SEQUENCING DURING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEGINTRON (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN HCV (GT1)-INFECTED PATIENTS. Journal of Hepatology. 54. S176–S176. 6 indexed citations

Flamm, S., E. Läwitz, Ira M. Jacobson, et al.. (2011). 1366 HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN. Journal of Hepatology. 54. S541–S542. 19 indexed citations

Esteban, Rafael, S. Gordon, Eric Lawitz, et al.. (2011). 418 UTILITY OF HISTORICAL DATA COMPARED TO LEAD-IN RESPONSE IN PREDICTING SUSTAINED VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR+PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R). Journal of Hepatology. 54. S168–S169.

Sulkowski, Mark, M. Shiffman, Jonathan McCone, et al.. (2009). 126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY. Journal of Hepatology. 50. S51–S52. 3 indexed citations

Kwo, Paul Y., E. Läwitz, Jonathan McCone, et al.. (2009). 4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C. Journal of Hepatology. 50. S4–S4. 66 indexed citations

10.

Sulkowski, Mark, E. Läwitz, M. Shiffman, et al.. (2008). 991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY. Journal of Hepatology. 48. S370–S371. 29 indexed citations

11.

Kwo, Paul Y., E. Läwitz, Jonathan McCone, et al.. (2008). 995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC. Journal of Hepatology. 48. S372–S372. 31 indexed citations

12.

Saldanha, J., et al.. (2005). World Health Organization collaborative study to establish a replacement WHO international standard for hepatitis C virus RNA nucleic acid amplification technology assays. Vox Sanguinis. 88(3). 202–204. 34 indexed citations

13.

Saldanha, J., et al.. (2003). WHO Collaborative Study to Establish a Replacement WHO International Standard for HCV RNA NAT Assays. 1 indexed citations

14.

Bystryn, J C, J. Albrecht, Sandra R. Reynolds, et al.. (2001). Decrease in Circulating Tumor Cells as an Early Marker of Therapy Effectiveness. Recent results in cancer research. 158. 204–207. 4 indexed citations

15.

Möslein, Gabriela, et al.. (2001). [Preventive therapy of HNPCC--a study concept].. PubMed. 118. 213–7. 1 indexed citations

16.

Poynard, Thierry, et al.. (2001). Durability of viral response to interferon ribavirin combination in patients with chronic hepatitis C. Journal of Hepatology. 34. 23–23. 9 indexed citations

17.

Trépo, Christian, Karen L. Lindsay, C. Niederau, et al.. (2000). Pegylated interferon alfa-2B (PEG-intron) mono-therapy is superior to interferon alfa-2B (intron A) for the treatment of chronic hepatitis C. Journal of Hepatology. 32. 29–29. 23 indexed citations

18.

Lindsay, Karen L., Gerald L. Davis, Eugene R. Schiff, et al.. (1996). Response to Higher Doses of Interferon Alfa–2B in Patients With Chronic Hepatitis C: A Randomized Multicenter Trial. Hepatology. 24(5). 1034–1040. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact